This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Xalkori® (crizotinib) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Video Resources

Best practices for ROS1 testing in NSCLC patients
Prof. Andrew Nicholson

Duration: 06:32
​​​​​​​
Should we be reflex-ROS1 testing on ALL lung cancer patients? Professor Nicholson gives his professional opinion on this question and others, including tips for laboratories who want to validate their own ROS1 testing service.

View

Tissue sample acquisition in NSCLC patients
Dr Neal Navani

Duration: 05:12​​​​​​​​​​​​​​

Dr Neal Navani answers the key question: "What is the importance of optimal tissue acquisition in lung cancer patients?" and gives his recommendations on optimal sample acquisition.

View

The optimal model for molecular testing in patients with advanced ROS1+ NSCLC 
​​​​​​​Dr Tim Benepal

Duration: 02:29

Dr Tim Benepal describes his vision of the optimal testing model for molecular testing by answering two significant questions: Should all molecular testing be carried out in-house? And when in a patient’s diagnostic pathway should these tests be requested?

View
References
  1. XALKORI Summary of Product Characteristics.
PP-XLK-GBR-1175. March 2021

Indication

XALKORI as a monotherapy is indicated for:1

  • The first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
  • The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
  • The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)

Register to receive tailored information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No